SV2B Promotes the Progression of TFE3‐Rearranged Renal Cell Carcinoma by Interacting with HERC2 to Impede the Degradation of NF‐κB Subunits
Advanced Science · 2026
DOI: 10.1002/advs.202509443 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Huayi Feng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, 100039, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, NF-kappa B, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Fostering Fund of Chinese PLA General Hospital for National Excellent Young Scholar Science Fund, National Key Research and Development Program and Clinical Key Specialty Construction Program.
Abstract (Originalsprache)
TFE3‐rearranged renal cell carcinoma (TFE3‐RCC) represents an aggressive subtype of renal cancer characterized by a poor prognosis, yet lacking clearly defined diagnostic and therapeutic targets. Here, the study demonstrates that synaptic vesicle protein 2B (SV2B) is a potential diagnostic marker and therapeutic target for TFE3‐RCC. SV2B , identified as a TFE3 target gene, is significantly upregulated in TFE3‐RCC and displays high diagnostic accuracy for this subtype. Functionally, SV2B enhances the proliferation, migration, and invasion of TFE3‐RCC cells. Mechanistically, SV2B competes with RELA/NFKB1 for binding to the E3 ligase HERC2, preventing their degradation and activating the NF‐κB pathway. The drug padsevonil, targeting SV2B, selectively inhibits the growth of TFE3‐RCC cells and organoids, similar to the NF‐κB inhibitor Withaferin A. Clinically, RELA/NFKB1 expression positively correlates with SV2B levels but negatively with HERC2 expression, confirming the activation of TFE3‐SV2B‐NF‐κB axis in TFE3‐RCC. These findings establish SV2B as a novel diagnostic biomarker for TFE3‐RCC and validate SV2B‐NF‐κB signaling as a therapeutic target, providing potential strategies for managing TFE3‐RCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, The Third Medical Center, Chinese PLA General Hospital, Beijing, 100039, China.
- Department of Urology, General Hospital of Central Theatre Command, Wuhan, 430070, China.
- Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China.
ORCID-Profile: Xiubin Li
Förderung
- National Natural Science Foundation of China
- Fostering Fund of Chinese PLA General Hospital for National Excellent Young Scholar Science Fund
- National Key Research and Development Program and Clinical Key Specialty Construction Program
- Growth Project of the Youth Independent Innovation Science Fund of Chinese PLA General Hospital
Zitieren
APA
Feng, H., Xiong, Z., Yu, S., Liu, J., Cao, S., Liu, K., Huang, X., Wen, L., Wang, B., Huang, Q., Pan, T., Zhang, X., Ma, X., & Li, X. (2026). SV2B Promotes the Progression of TFE3‐Rearranged Renal Cell Carcinoma by Interacting with HERC2 to Impede the Degradation of NF‐κB Subunits. Advanced Science. https://doi.org/10.1002/advs.202509443
Vancouver
Feng H, Xiong Z, Yu S, Liu J, Cao S, Liu K, et al. SV2B Promotes the Progression of TFE3‐Rearranged Renal Cell Carcinoma by Interacting with HERC2 to Impede the Degradation of NF‐κB Subunits. Advanced Science. 2026. doi:10.1002/advs.202509443
BibTeX
@article{Feng2026,
author = {Feng, Huayi and Xiong, Zhuang and Yu, Shaoqing and Liu, Junxiao and Cao, Shouqing and Liu, Kan and Huang, Xing and Wen, Lequan and Wang, Baojun and Huang, Qingbo and Pan, Tiejun and Zhang, Xu and Ma, Xin and Li, Xiubin},
title = {SV2B Promotes the Progression of TFE3‐Rearranged Renal Cell Carcinoma by Interacting with HERC2 to Impede the Degradation of NF‐κB Subunits},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202509443}
}
EUVIMED